231 related articles for article (PubMed ID: 31183500)
1. Compassionate Use of Letermovir in a 2-Year-Old Immunocompromised Child With Resistant Cytomegalovirus Disease.
Pérez Marín M; Decosterd LA; Andre P; Buclin T; Mercier T; Murray K; Rizzi M; Meylan P; Jaton-Ogay K; Opota O; Gengler C; Perez MH; Natterer J; Asner SA
J Pediatric Infect Dis Soc; 2020 Feb; 9(1):96-99. PubMed ID: 31183500
[TBL] [Abstract][Full Text] [Related]
2. Preemptive treatment of Cytomegalovirus infection in kidney transplant recipients with letermovir: results of a Phase 2a study.
Stoelben S; Arns W; Renders L; Hummel J; Mühlfeld A; Stangl M; Fischereder M; Gwinner W; Suwelack B; Witzke O; Dürr M; Beelen DW; Michel D; Lischka P; Zimmermann H; Rübsamen-Schaeff H; Budde K
Transpl Int; 2014 Jan; 27(1):77-86. PubMed ID: 24164420
[TBL] [Abstract][Full Text] [Related]
3. Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection.
Cherrier L; Nasar A; Goodlet KJ; Nailor MD; Tokman S; Chou S
Am J Transplant; 2018 Dec; 18(12):3060-3064. PubMed ID: 30286286
[TBL] [Abstract][Full Text] [Related]
4. Single-center experience with use of letermovir for CMV prophylaxis or treatment in thoracic organ transplant recipients.
Aryal S; Katugaha SB; Cochrane A; Brown AW; Nathan SD; Shlobin OA; Ahmad K; Marinak L; Chun J; Fregoso M; Desai S; King C
Transpl Infect Dis; 2019 Dec; 21(6):e13166. PubMed ID: 31487755
[TBL] [Abstract][Full Text] [Related]
5. Letermovir successfully used for secondary prophylaxis in a heart transplant recipient with ganciclovir-resistant cytomegalovirus syndrome (UL97 mutation).
Chong PP; Teiber D; Prokesch BC; Arasaratnam RJ; Peltz M; Drazner MH; Garg S
Transpl Infect Dis; 2018 Oct; 20(5):e12965. PubMed ID: 29989279
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic drug evaluation of letermovir prophylaxis for cytomegalovirus in hematopoietic stem cell transplantation.
Deleenheer B; Spriet I; Maertens J
Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1197-1207. PubMed ID: 30479172
[TBL] [Abstract][Full Text] [Related]
7. Letermovir for the compassionate therapeutic use of cytomegalovirus infection.
Schubert L; Fisecker L; Thalhammer F; Burgmann H; Steininger C
Eur J Clin Microbiol Infect Dis; 2021 Feb; 40(2):435-439. PubMed ID: 32914220
[TBL] [Abstract][Full Text] [Related]
8. Use of Letermovir for Salvage Therapy for Resistant Cytomegalovirus in a Pediatric Hematopoietic Stem Cell Transplant Recipient.
Kilgore JT; Becken B; Varga MG; Parikh S; Prasad V; Lugo D; Chang YC
J Pediatric Infect Dis Soc; 2020 Sep; 9(4):486-489. PubMed ID: 31362308
[TBL] [Abstract][Full Text] [Related]
9. Successful Treatment of UL97 Mutation Ganciclovir-Resistant Cytomegalovirus Viremia in a Renal Transplant Recipient With Letermovir and Adjunct Hyperimmune Cytomegalovirus Immunoglobulin: A Case Report.
Pearston AP; Ingemi AI; Ripley K; Wilson TJ; Gruber J; McMahon M; Sutton S; Khardori N
Transplant Proc; 2021 May; 53(4):1284-1287. PubMed ID: 33715819
[TBL] [Abstract][Full Text] [Related]
10. An overview of letermovir: a cytomegalovirus prophylactic option.
Gerna G; Lilleri D; Baldanti F
Expert Opin Pharmacother; 2019 Aug; 20(12):1429-1438. PubMed ID: 31282759
[No Abstract] [Full Text] [Related]
11. [Current treatment modalities of immunocompromised patients with cytomegalovirus infection. II. Therapeutic options and management strategies].
Sinkó J
Orv Hetil; 2019 Mar; 160(10):363-369. PubMed ID: 30829057
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and safety of the anti-human cytomegalovirus drug letermovir in subjects with hepatic impairment.
Kropeit D; McCormick D; Erb-Zohar K; Moiseev VS; Kobalava ZD; Stobernack HP; Zimmermann H; Rübsamen-Schaeff H
Br J Clin Pharmacol; 2017 Dec; 83(12):2678-2686. PubMed ID: 28722153
[TBL] [Abstract][Full Text] [Related]
13. Letermovir for the management of cytomegalovirus infection.
Bowman LJ; Melaragno JI; Brennan DC
Expert Opin Investig Drugs; 2017 Feb; 26(2):235-241. PubMed ID: 27998189
[TBL] [Abstract][Full Text] [Related]
14. Maribavir, brincidofovir and letermovir: Efficacy and safety of new antiviral drugs for treating cytomegalovirus infections.
Frange P; Leruez-Ville M
Med Mal Infect; 2018 Dec; 48(8):495-502. PubMed ID: 29650261
[TBL] [Abstract][Full Text] [Related]
15. Letermovir (Prevymis) for CMV prophylaxis.
Med Lett Drugs Ther; 2019 Dec; 61(1587):199-201. PubMed ID: 31999668
[No Abstract] [Full Text] [Related]
16. Characterization of Cytomegalovirus Breakthrough Events in a Phase 2 Prophylaxis Trial of Letermovir (AIC246, MK 8228).
Lischka P; Michel D; Zimmermann H
J Infect Dis; 2016 Jan; 213(1):23-30. PubMed ID: 26113373
[TBL] [Abstract][Full Text] [Related]
17. Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation.
Chemaly RF; Ullmann AJ; Stoelben S; Richard MP; Bornhäuser M; Groth C; Einsele H; Silverman M; Mullane KM; Brown J; Nowak H; Kölling K; Stobernack HP; Lischka P; Zimmermann H; Rübsamen-Schaeff H; Champlin RE; Ehninger G;
N Engl J Med; 2014 May; 370(19):1781-9. PubMed ID: 24806159
[TBL] [Abstract][Full Text] [Related]
18. Combination Treatment With Letermovir and Ganciclovir for Maintenance Therapy of Multidrug-resistant CMV Infection in a Liver Transplant Recipient.
Kronig I; Elkrief L; Berney T; Van Delden C; Neofytos D
Transplantation; 2020 Aug; 104(8):e248-e249. PubMed ID: 32732860
[No Abstract] [Full Text] [Related]
19. Letermovir: First Global Approval.
Kim ES
Drugs; 2018 Jan; 78(1):147-152. PubMed ID: 29288370
[TBL] [Abstract][Full Text] [Related]
20. Fast breakthrough of resistant cytomegalovirus during secondary letermovir prophylaxis in a hematopoietic stem cell transplant recipient.
Jung S; Michel M; Stamminger T; Michel D
BMC Infect Dis; 2019 May; 19(1):388. PubMed ID: 31068147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
